CIK: 0002026172
Total reported value
$587.7M
Reporting period: 2026-03-31 · Number of holdings: 144
DIADEMA PARTNERS LP disclosed 144 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $587.7M and a quarterly turnover rate of 101.5%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "D"
Diadema Partners LP's disclosed holdings carry a Herfindahl concentration index of 0.036 — mathematically equivalent to about 28 equally-sized positions, well below its 144 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.73), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 52% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add UTHR
+775.0% $47.0M
Add LQDA
+3154.4% $26.1M
Trim BBIO
-79.2% -$25.0M
Add ABVX
+264.8% $20.3M
Add RVMD
+457.5% $17.1M
Add KOD
+1386.7% $15.9M
Showing top 111 holdings (of 144 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 8.83% | +7.99% | +775.03% | |
| 2 | VRTX | Vertex Pharmaceuticals INC | Stock-Healthcare | 7.37% | — | -1.38% | |
| 3 | VKTX | Viking Therapeutics INC | Stock-Healthcare | 6.56% | -1.58% | -11.77% | |
| 4 | CAPR | Capricor Therapeutics INC | Stock-Other | 5.34% | +2.01% | +53.88% | |
| 5 | ABVX | Abivax Sa-adr | Stock-Other | 5.19% | +3.43% | +264.79% | |
| 6 | LQDA | Liquidia CORP | Stock-Other | 4.57% | +4.44% | +3154.42% | |
| 7 | RVMD | Revolution Medicines INC | Stock-Healthcare | 3.41% | +2.90% | +457.46% | |
| 8 | APGE | Apogee Therapeutics INC | Stock-Other | 3.19% | +0.45% | +5.40% | |
| 9 | BBIO 1.75 03-01-31 | Bridgebio Pharma INC | Stock-Healthcare | 3.16% | +3.16% | NEW | |
| 10 | INCY | Incyte CORP | Stock-Healthcare | 2.94% | +1.24% | +83.43% | |
| 11 | KOD | Kodiak Sciences INC | Stock-Other | 2.85% | +2.71% | +1386.70% | |
| 12 | CYTK | Cytokinetics INC | Stock-Healthcare | 2.80% | +2.80% | NEW | |
| 13 | JNJ | Johnson & Johnson | Stock-Healthcare | 2.24% | -1.91% | -53.82% | |
| 14 | COGT | Cogent Biosciences INC | Stock-Other | 2.11% | +1.30% | +144.79% | |
| 15 | MRK | Merck & Co. INC. | Stock-Healthcare | 2.05% | +2.05% | NEW | |
| 16 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.76% | -1.32% | -48.00% | |
| 17 | GPCR | Structure Therapeutics INC | Stock-Other | 1.64% | -0.66% | +4.19% | |
| 18 | 430 | Terns Pharmaceuticals INC | Stock-Other | 1.63% | -1.23% | -55.73% | |
| 19 | QURE | uniQure N.V. | Stock-Other | 1.61% | — | +67.30% | |
| 20 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.58% | — | +5.37% | |
| 21 | BMRN | Biomarin Pharmaceutical INC | Stock-Healthcare | 1.42% | — | +1.28% | |
| 22 | MRNA | Moderna INC | Stock-Healthcare | 1.38% | +1.38% | NEW | |
| 23 | TGTX | Tg Therapeutics INC | Stock-Healthcare | 1.17% | — | -7.32% | |
| 24 | CORT | Corcept Therapeutics INC | Stock-Healthcare | 1.16% | — | -27.45% | |
| 25 | EWTX | Edgewise Therapeutics INC | Stock-Other | 1.14% | +1.01% | +608.33% | |
| 26 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 1.08% | -4.32% | -79.17% | |
| 27 | REPL | Replimune Group INC | Stock-Other | 1.00% | +0.61% | +231.63% | |
| 28 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.99% | +0.57% | +174.81% | |
| 29 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.94% | +0.57% | +200.00% | |
| 30 | ABBV | Abbvie INC | Stock-Healthcare | 0.89% | +0.89% | NEW | |
| 31 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.89% | +0.89% | NEW | |
| 32 | RCUS | Arcus Biosciences INC | Stock-Other | 0.88% | +0.88% | NEW | |
| 33 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 0.87% | +0.80% | +561.23% | |
| 34 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.86% | — | -5.68% | |
| 35 | PCVX | Vaxcyte INC | Stock-Other | 0.77% | +0.59% | +240.29% | |
| 36 | EYPT | Eyepoint INC | Stock-Other | 0.62% | +0.62% | NEW | |
| 37 | ZYME | Zymeworks INC | Stock-Other | 0.61% | -0.58% | -45.75% | |
| 38 | GLUE | Monte Rosa Therapeutics INC | Stock-Other | 0.52% | — | +200.75% | |
| 39 | ALMS | Alumis INC | Stock-Other | 0.49% | +0.49% | NEW | |
| 40 | TENX | Tenax Therapeutics INC | Stock-Other | 0.49% | — | -26.09% | |
| 41 | ANNX | Annexon INC | Stock-Other | 0.46% | — | -26.25% | |
| 42 | BHVN | Biohaven Ltd. | Stock-Other | 0.46% | — | +58.50% | |
| 43 | CELC | Celcuity INC | Stock-Other | 0.45% | +0.45% | NEW | |
| 44 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.44% | — | +1138.19% | |
| 45 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 0.44% | — | +32.73% | |
| 46 | NTLA | Intellia Therapeutics INC | Stock-Other | 0.44% | — | -62.21% | |
| 47 | VYGR | Voyager Therapeutics INC | Stock-Other | 0.38% | — | — | |
| 48 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.38% | — | — | |
| 49 | INDV | Indivior Pharmaceuticals INC | Stock-Other | 0.37% | — | — | |
| 50 | CLYM | Climb Bio INC | Stock-Other | 0.33% | — | — |
Performance for Q3 2026
+20%
Performance Last 4 Quarters
+75.9%
Based on 67% of reported portfolio value with available pricing
Diadema Partners LP's most significant position changes for 2026-03-31: Sold out: Ss Spdr S&p Biotech ETF (XBI); Sold out: Praxis Precision Medicines I (PRAX); Sold out: Avidity Biosciences INC (RNAGBP); New buy: Bridgebio Pharma INC (BBIO 1.75 03-01-31); Sold out: Invesco Qqq Trust Series 1 (QQQ).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | +8% | +775.03% | Add |
| 2 | LQDA | Liquidia CORP | +4.4% | +3154.42% | Add |
| 3 | ABVX | Abivax Sa-adr | +3.4% | +264.79% | Add |
| 4 | RVMD | Revolution Medicines INC | +2.9% | +457.46% | Add |
| 5 | KOD | Kodiak Sciences INC | +2.7% | +1386.70% | Add |
| 6 | CAPR | Capricor Therapeutics INC | +2% | +53.88% | Add |
| 7 | COGT | Cogent Biosciences INC | +1.3% | +144.79% | Add |
| 8 | INCY | Incyte CORP | +1.2% | +83.43% | Add |
| 9 | EWTX | Edgewise Therapeutics INC | +1% | +608.33% | Add |
| 10 | CRVS | Corvus Pharmaceuticals INC | +0.8% | +561.23% | Add |
| 11 | REPL | Replimune Group INC | +0.6% | +231.63% | Add |
| 12 | PCVX | Vaxcyte INC | +0.6% | +240.29% | Add |
| 13 | IMCR | Immunocore Holdings Plc-adr | +0.6% | +174.81% | Add |
| 14 | LLY | Eli Lilly & Co | +0.6% | +200.00% | Add |
| 15 | APGE | Apogee Therapeutics INC | +0.5% | +5.40% | Add |
| 16 | BIOA | Bioage Labs INC | -0.5% | -79.58% | Trim |
| 17 | ZYME | Zymeworks INC | -0.6% | -45.75% | Trim |
| 18 | GPCR | Structure Therapeutics INC | -0.7% | +4.19% | Add |
| 19 | MNKD | Mannkind CORP | -0.8% | -78.16% | Trim |
| 20 | 430 | Terns Pharmaceuticals INC | -1.2% | -55.73% | Trim |
| 21 | JAZZ | Jazz Pharmaceuticals plc | -1.3% | -48.00% | Trim |
| 22 | VKTX | Viking Therapeutics INC | -1.6% | -11.77% | Trim |
| 23 | JNJ | Johnson & Johnson | -1.9% | -53.82% | Trim |
| 24 | BBIO | Bridgebio Pharma INC | -4.3% | -79.17% | Trim |
| 25 | XBI | Ss Spdr S&p Biotech ETF | — | EXIT | Sold out |
| 26 | PRAX | Praxis Precision Medicines I | — | EXIT | Sold out |
| 27 | RNAGBP | Avidity Biosciences INC | — | EXIT | Sold out |
| 28 | BBIO 1.75 03-01-31 | Bridgebio Pharma INC | — | NEW | New buy |
| 29 | QQQ | Invesco Qqq Trust Series 1 | — | EXIT | Sold out |
| 30 | CYTK | Cytokinetics INC | — | NEW | New buy |
| 31 | MRK | Merck & Co. INC. | — | NEW | New buy |
| 32 | REGN | Regeneron Pharmaceuticals | — | EXIT | Sold out |
| 33 | INSM | Insmed INC | — | EXIT | Sold out |
| 34 | INDV | Indivior Pharmaceuticals, Inc. | — | EXIT | Sold out |
| 35 | IONS | Ionis Pharmaceuticals INC | — | EXIT | Sold out |
| 36 | MRNA | Moderna INC | — | NEW | New buy |
| 37 | OCUL | Ocular Therapeutix INC | — | EXIT | Sold out |
| 38 | ABBV | Abbvie INC | — | NEW | New buy |
| 39 | CRBP | Corbus Pharmaceuticals Holdi | — | NEW | New buy |
| 40 | RCUS | Arcus Biosciences INC | — | NEW | New buy |
| 41 | ANIP | Ani Pharmaceuticals INC | — | EXIT | Sold out |
| 42 | SLNOEUR | Soleno Therapeutics INC | — | EXIT | Sold out |
| 43 | EYPT | Eyepoint INC | — | NEW | New buy |
| 44 | AQST | Aquestive Therapeutics INC | — | EXIT | Sold out |
| 45 | RXRX | Recursion Pharmaceuticals-a | — | EXIT | Sold out |
| 46 | ALMS | Alumis INC | — | NEW | New buy |
| 47 | 260 | Centessa Pharmaceuticals-adr | — | EXIT | Sold out |
| 48 | GOSS | Gossamer Bio INC | — | EXIT | Sold out |
| 49 | ABUS | Arbutus Biopharma CORP | — | EXIT | Sold out |
| 50 | CELC | Celcuity INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002039437
Total reported value
$587.5M
73 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001008868
Total reported value
$587.4M
101 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001587192
Total reported value
$588.1M
337 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001697013
Total reported value
$1.9B
120 stks
2026-03-31
2 of the top 5 holdings overlap, including United Therapeutics CORP
CIK 0001993440
Total reported value
$895.1M
33 stks
2026-03-31
2 of the top 5 holdings overlap, including United Therapeutics CORP
CIK 0002102314
Total reported value
$466.5M
26 stks
2026-03-31
2 of the top 5 holdings overlap, including Vertex Pharmaceuticals INC